Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Herboxidiene (GEX1A) is a natural polyketide isolated from *Streptomyces chromofuscus* that acts as a potent small molecule spliceosome modulator. It exerts its biological activity by specifically binding to the SAP155 subunit of the Splicing Factor 3B subunit 1 (SF3B1), a component of the U2 small nuclear ribonucleoprotein (snRNP) complex. This binding interferes with the recognition of the branch point adenosine during pre-mRNA splicing. In the context of oncology, particularly hematologic malignancies like acute myeloid leukemia (AML), herboxidiene induces a splice isoform shift of the anti-apoptotic protein MCL-1 to its pro-apoptotic variant, MCL-1S. It also facilitates the conversion of pro-survival BCL-2 into a pro-apoptotic mediator through interactions with the orphan nuclear receptor Nur77 (NR4A1) and represses the expression of oncogenic drivers such as FLT3-ITD. Additionally, it has been shown to target leukemia stem cells by inhibiting the mitochondrial isoform of FASTK. Beyond oncology, research suggests herboxidiene may have utility in treating Niemann-Pick type C1 by correcting associated cellular defects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on herboxidiene.